Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03481738 · ClinicalTrials.gov registry record
Pyruvate Kinase Deficiency Global Longitudinal Registry
A clinical trial of Pyruvate Kinase Deficiency, sponsored by Agios Pharmaceuticals.
- Active
- Registry status
- 500
- Enrollment target
- 20
- Study locations
NCT03481738 is a study of Pyruvate Kinase Deficiency that is active but no longer recruiting, run by Agios Pharmaceuticals. The registered enrollment target is 500 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT03481738, a study of Pyruvate Kinase Deficiency, is active but no longer recruiting, sponsored by Agios Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is an observational (ie, noninterventional), longitudinal, multicenter, global registry for patients with pyruvate kinase (PK) deficiency, a rare nonspherocytic hemolytic anemia. This Registry will be open for enrollment for 7 years and all enrolled participants will be followed prospectively for a minimum of 2 years, and up to 9 years. Data will be collected from participating Registry Physicians, participants, and, where appropriate, parents/guardians who have provided informed consent or assent (where relevant) and authorization pursuant to applicable laws and regulations. Data should include demographic, clinical, and treatment data; and other data of relevance to the management of patients with PK deficiency. Annual chart review and data entry are expected in order to enhance longitudinal understanding of PK deficiency; however, no specific protocol schedule of assessment is required by this Registry protocol.
Conditions Studied
Study Locations (20)
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Children's Hospital - Boston
- UMass Memorial Medical Center - Worcester
Arkansas
- Arkansas Children's Hospital - Little Rock
- University of Arkansas for Medical Sciences - Little Rock
California
- Children's Hospital of Orange County - Orange
- Stanford University Medical Center - Palo Alto
Ontario
- Saint Josephs Healthcare System - Hamilton
- Toronto General Hospital - Toronto
Other
- Fakultni nemocnice Olomouc - Olomouc
- Ustav hematologie a krevni transfuze - Prague
Arizona
- Phoenix Childrens Hospital - Phoenix
Georgia
- Children's Healthcare of Atlanta - Atlanta
Michigan
- Children's Hospital of Michigan - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2018-04-23 |
| Est. Completion | 2027-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03481738
The ClinicalTrials.gov registry entry for NCT03481738 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agios Pharmaceuticals, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pyruvate Kinase Deficiency appearing as the primary indexed condition, and to 0 interventions.
NCT03481738 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Massachusetts, Arkansas, California.
Frequently Asked Questions
What is clinical trial NCT03481738 about?
NCT03481738 is a clinical study titled "Pyruvate Kinase Deficiency Global Longitudinal Registry". This study is an observational (ie, noninterventional), longitudinal, multicenter, global registry for patients with pyruvate kinase (PK) deficiency, a rare nonspherocytic hemolytic anemia. This Registry will be open for enrollment for 7 years and all enrolled participants will be followed prospect...
What is the current status of trial NCT03481738?
This trial is currently active not recruiting. The enrollment target is 500 participants. The study started on 2018-04-23. Estimated completion is 2027-05-31.
What conditions does trial NCT03481738 study?
This clinical trial studies the following conditions: Pyruvate Kinase Deficiency.
Who is sponsoring clinical trial NCT03481738?
This trial is sponsored by Agios Pharmaceuticals, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03481738 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pyruvate Kinase Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.